Creative Medical Technology (CELZ) Competitors $2.20 0.00 (0.00%) As of 06/12/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELZ vs. GDTC, NNVC, QTTB, MIRA, RLMD, XFOR, CALC, LSTA, ENLV, and CASIShould you be buying Creative Medical Technology stock or one of its competitors? The main competitors of Creative Medical Technology include CytoMed Therapeutics (GDTC), NanoViricides (NNVC), Q32 Bio (QTTB), MIRA Pharmaceuticals (MIRA), Relmada Therapeutics (RLMD), X4 Pharmaceuticals (XFOR), CalciMedica (CALC), Lisata Therapeutics (LSTA), Enlivex Therapeutics (ENLV), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry. Creative Medical Technology vs. Its Competitors CytoMed Therapeutics NanoViricides Q32 Bio MIRA Pharmaceuticals Relmada Therapeutics X4 Pharmaceuticals CalciMedica Lisata Therapeutics Enlivex Therapeutics CASI Pharmaceuticals Creative Medical Technology (NASDAQ:CELZ) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Is CELZ or GDTC more profitable? CytoMed Therapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity.Company Net Margins Return on Equity Return on Assets Creative Medical TechnologyN/A -63.05% -60.42% CytoMed Therapeutics N/A N/A N/A Which has stronger valuation and earnings, CELZ or GDTC? CytoMed Therapeutics has higher revenue and earnings than Creative Medical Technology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCreative Medical Technology$14K406.37-$5.29M-$3.81-0.58CytoMed Therapeutics$69.50K335.28-$3.13MN/AN/A Do insiders & institutionals believe in CELZ or GDTC? 1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 2.8% of Creative Medical Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in CELZ or GDTC? Creative Medical Technology received 67 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 68.27% of users gave Creative Medical Technology an outperform vote. CompanyUnderperformOutperformCreative Medical TechnologyOutperform Votes7168.27% Underperform Votes3331.73% CytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes Which has more risk and volatility, CELZ or GDTC? Creative Medical Technology has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Do analysts recommend CELZ or GDTC? CytoMed Therapeutics has a consensus price target of $5.00, indicating a potential upside of 134.74%. Given CytoMed Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytoMed Therapeutics is more favorable than Creative Medical Technology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer CELZ or GDTC? In the previous week, Creative Medical Technology had 5 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 6 mentions for Creative Medical Technology and 1 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.89 beat Creative Medical Technology's score of -0.35 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Creative Medical Technology Neutral CytoMed Therapeutics Very Positive SummaryCytoMed Therapeutics beats Creative Medical Technology on 9 of the 15 factors compared between the two stocks. Get Creative Medical Technology News Delivered to You Automatically Sign up to receive the latest news and ratings for CELZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELZ vs. The Competition Export to ExcelMetricCreative Medical TechnologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.69M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-0.5832.9027.1419.96Price / Sales406.37466.20416.10157.63Price / CashN/A168.6838.2534.64Price / Book0.293.427.074.69Net Income-$5.29M-$72.35M$3.23B$248.14M7 Day Performance-7.95%2.59%0.71%0.91%1 Month Performance10.00%20.47%9.65%5.71%1 Year Performance-47.12%-17.11%32.07%14.71% Creative Medical Technology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELZCreative Medical Technology0.4547 of 5 stars$2.20flatN/A-47.4%$5.69M$14K-0.585Short Interest ↑Gap UpGDTCCytoMed Therapeutics2.6321 of 5 stars$2.16-7.7%$5.00+131.5%+2.4%$23.63M$69.50K0.00N/ANNVCNanoViricides0.1306 of 5 stars$1.47-4.5%N/A-38.4%$23.63MN/A-2.0420Short Interest ↑QTTBQ32 Bio3.4417 of 5 stars$1.92+4.9%$24.71+1,187.2%-91.2%$23.42M-$6.65M-0.1339Positive NewsShort Interest ↓MIRAMIRA Pharmaceuticals3.3806 of 5 stars$1.38-0.7%$14.00+914.5%+67.6%$23.35MN/A-2.462Positive NewsShort Interest ↓RLMDRelmada Therapeutics4.8239 of 5 stars$0.70-1.6%$4.25+509.5%-76.7%$23.15MN/A-0.2410Positive NewsXFORX4 Pharmaceuticals4.3689 of 5 stars$3.96+3.9%$72.33+1,726.6%-90.8%$22.92M$31.36M-44.0080News CoverageShort Interest ↑Analyst RevisionHigh Trading VolumeCALCCalciMedica2.7527 of 5 stars$1.63-0.6%$18.00+1,004.3%-65.4%$22.77MN/A-1.5130News CoverageGap UpLSTALisata Therapeutics2.4889 of 5 stars$2.60-5.1%$15.00+476.9%-25.3%$22.40M$1M-1.0430ENLVEnlivex Therapeutics3.4817 of 5 stars$0.94+0.0%$10.00+963.5%-32.4%$22.24MN/A-0.9670CASICASI Pharmaceuticals4.4004 of 5 stars$1.81-2.3%$4.00+121.6%-44.4%$22.20M$31.37M-0.81180 Related Companies and Tools Related Companies CytoMed Therapeutics Alternatives NanoViricides Alternatives Q32 Bio Alternatives MIRA Pharmaceuticals Alternatives Relmada Therapeutics Alternatives X4 Pharmaceuticals Alternatives CalciMedica Alternatives Lisata Therapeutics Alternatives Enlivex Therapeutics Alternatives CASI Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELZ) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Creative Medical Technology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Creative Medical Technology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
